Search

Your search keyword '"Clausen, Michael"' showing total 749 results
Start Over Author "Clausen, Michael"
749 results on '"Clausen, Michael"'

1. Epcoritamab in relapsed/refractory large B-cell lymphoma: 2-year follow-up from the pivotal EPCORE NHL-1 trial

Author

Thieblemont, Catherine, Karimi, Yasmin H., Ghesquieres, Herve, Cheah, Chan Y., Clausen, Michael Roost, Cunningham, David, Jurczak, Wojciech, Do, Young Rok, Gasiorowski, Robin, Lewis, David John, Kim, Tae Min, van der Poel, Marjolein, Poon, Michelle Limei, Feldman, Tatyana, Linton, Kim M., Sureda, Anna, Hutchings, Martin, Dinh, Minh H., Kilavuz, Nurgul, Soong, David, Mark, Thomas, Sacchi, Mariana, Phillips, Tycel, and Lugtenburg, Pieternella J.

Published
2024
Full Text
View/download PDF

3. Epcoritamab monotherapy in patients with relapsed or refractory follicular lymphoma (EPCORE NHL-1): a phase 2 cohort of a single-arm, multicentre study

Author

Linton, Kim M, Vitolo, Umberto, Jurczak, Wojciech, Lugtenburg, Pieternella J, Gyan, Emmanuel, Sureda, Anna, Christensen, Jacob Haaber, Hess, Brian, Tilly, Hervé, Cordoba, Raul, Lewis, David John, Okada, Craig, Hutchings, Martin, Clausen, Michael Roost, Sancho, Juan-Manuel, Cochrane, Tara, Leppä, Sirpa, Chamuleau, Martine E D, Gernhardt, Diana, Altıntaş, Işıl, Liu, Yan, Ahmadi, Tahamtan, Dinh, Minh H, Hoehn, Daniela, Favaro, Elena, Elliott, Brian, Thieblemont, Catherine, and Vose, Julie M

Published
2024
Full Text
View/download PDF

7. Risk of diabetes and the impact on preexisting diabetes in patients with lymphoma treated with steroid-containing immunochemotherapy

Author

Baech, Joachim, Severinsen, Marianne Tang, Øvlisen, Andreas K., Frederiksen, Henrik, Vestergaard, Peter, Torp-Pedersen, Christian, Jørgensen, Judit, Clausen, Michael Roost, Poulsen, Christian B., Brown, Peter, Gang, Anne Ortved, Pedersen, Robert Schou, Ekström Smedby, Karin, Eloranta, Sandra, Jakobsen, Lasse Hjort, and El-Galaly, Tarec Christoffer

Published
2022
Full Text
View/download PDF

8. Effectiveness of R‐CHOP versus R‐CHOEP for treatment of young patients with high‐risk diffuse large B‐cell lymphoma: A Danish observational population‐based study.

Author

Rask Kragh Jørgensen, Rasmus, Jakobsen, Lasse Hjort, Eloranta, Sandra, Smedby, Karin E., Pedersen, Robert Schou, Jørgensen, Judit M., Clausen, Michael Roost, Brown, Peter, Gang, Anne Ortved, Gade, Inger‐Lise, Larsen, Thomas Stauffer, Jerkeman, Mats, and El‐Galaly, Tarec Christoffer

Subjects
CANCER treatment, GENETIC techniques, DIFFUSE large B-cell lymphomas, OVERALL survival, TREATMENT effectiveness
Abstract

Purpose: Etoposide to standard R‐CHOP is used for high‐risk diffuse large B‐cell lymphoma (DLBCL) in some countries. Due to the lack of randomized trials, a real‐world data study using matching methods was used to test the potential effectiveness of R‐CHOEP over R‐CHOP. Patients and Methods: This study included patients from the Danish Lymphoma Register diagnosed between 2006 and 2020 at the age of 18–60 years with de novo DLBCL and age‐adjusted IPI ≥2. R‐CHOEP treated patients were matched 1:1 without replacement to R‐CHOP treated patients using a hybrid exact and genetic matching technique. Primary endpoints were progression‐free survival (PFS) and overall survival (OS). Results: In total, 396 patients were included; 213 received R‐CHOEP and 183 received R‐CHOP. Unadjusted 5‐year PFS and OS for R‐CHOEP were 69% (95% Confidence intervals [CI]; 63%–76%) and 79% (CI;73%–85%) versus 62% (CI;55%–70%) and 76% (CI;69%–82%) for R‐CHOP (log‐rank test, PFS p =.25 and OS p =.31). A total of 127 patients treated with R‐CHOEP were matched to 127 patients treated with R‐CHOP. Matching‐adjusted 5‐year PFS and OS were 65% (CI; 57%–74%) and 79% (CI; 72%–84%) for R‐CHOEP versus 63% (CI; 55%–73%) and 79% (CI;72%–87%) for R‐CHOP (log‐rank test, PFS p =.90 and OS p =.63). Conclusion: The present study did not confirm superiority of R‐CHOEP over R‐CHOP for young patients with high‐risk DLBCL. [ABSTRACT FROM AUTHOR]

Published
2024
Full Text
View/download PDF

10. Extended follow-up results beyond 2.5 years from the pivotal NHL-1 EPCORE trial: Subcutaneous epcoritamab monotherapy in patients with relapsed/refractory large B-cell lymphoma (R/R LBCL).

Author

Karimi, Yasmin, primary, Thieblemont, Catherine, additional, Ghesquieres, Hervé, additional, Cheah, Chan Y, additional, Clausen, Michael Roost, additional, Cunningham, David, additional, Jurczak, Wojciech, additional, Linton, Kim M., additional, Hutchings, Martin, additional, Phillips, Tycel Jovelle, additional, Farooq, Umar, additional, Kim, Won Seog, additional, Dinh, Minh H, additional, Ghosh, Jagannath, additional, Pallai, Rajash, additional, Wielgos-Bonvallet, Monica, additional, Eskelund, Christian, additional, Lugtenburg, Pieternella, additional, and Vose, Julie, additional

Published
2024
Full Text
View/download PDF

11. Dose escalation of subcutaneous epcoritamab in patients with relapsed or refractory B-cell non-Hodgkin lymphoma: an open-label, phase 1/2 study

Author

Hutchings, Martin, Mous, Rogier, Clausen, Michael Roost, Johnson, Peter, Linton, Kim M, Chamuleau, Martine E D, Lewis, David John, Sureda Balari, Anna, Cunningham, David, Oliveri, Roberto S, Elliott, Brian, DeMarco, Dena, Azaryan, Ada, Chiu, Christopher, Li, Tommy, Chen, Kuo-mei, Ahmadi, Tahamtan, and Lugtenburg, Pieternella J

Published
2021
Full Text
View/download PDF

12. A Real‐World Data‐Based Analysis of Prognostic Indices as Part of Trial Eligibility Criteria in Diffuse Large B‐Cell Lymphoma Patients.

Author

Jelicic, Jelena, Juul‐Jensen, Karen, Bukumiric, Zoran, Runason Simonsen, Mikkel, Roost Clausen, Michael, Ludvigsen Al‐Mashhadi, Ahmed, Schou Pedersen, Robert, Bjørn Poulsen, Christian, Ortved Gang, Anne, Brown, Peter, El‐Galaly, Tarec Christoffer, and Stauffer Larsen, Thomas

Abstract

Objectives: Recent front‐line clinical trials used the International Prognostic Index (IPI) to identify trial‐eligible patients with newly diagnosed diffuse large B‐cell lymphoma (DLBCL). However, many IPI‐like variants with improved accuracy have been developed over the years for rituximab‐treated patients. Methods: We assessed the impact of International Prognostic Indices on patient enrolment in clinical trials, aiming to exclude low‐risk IPI patients based on POLARIX/EPCORE DLBCL‐2 trial criteria. Results: We identified 2877 patients in the Danish Lymphoma Registry who would have been eligible for the POLARIX trial if patients with IPI 0–1 scores were included. IPI and NCCN‐IPI assigned 33.3% and 11.9% of patients to the low‐risk group, respectively. Shorter 5‐year overall survival (91.4% vs. 97.5%), higher relapse rate (9.9% vs. 4.4%), and more deaths (16.1% vs. 4.4%) occurred in the low‐risk IPI group compared with low‐risk NCCN‐IPI group. Analyzed models failed to identify true high‐risk patients with poor prognosis. Similar results were found in the confirmatory cohort developed based on EPCORE DLBCL‐2 trial eligibility criteria. Conclusion: True low‐risk patients are more optimal identified by NCCN‐IPI and should be excluded from front‐line clinical trials due to their excellent prognosis. However, additional high‐risk factors besides clinical prognostic models need to be considered when selecting trial‐eligible patients. [ABSTRACT FROM AUTHOR]

Published
2025
Full Text
View/download PDF

13. Walnut Allergy Across Europe: Distribution of Allergen Sensitization Patterns and Prediction of Severity

Author

Lyons, Sarah A., Datema, Mareen R., Le, Thuy-My, Asero, Riccardo, Barreales, Laura, Belohlavkova, Simona, de Blay, Frédéric, Clausen, Michael, Dubakiene, Ruta, Fernández-Perez, Cristina, Fritsche, Philipp, Gislason, David, Hoffmann-Sommergruber, Karin, Jedrzejczak-Czechowicz, Monika, Jongejan, Laurian, Kowalski, Marek L., Kralimarkova, Tanya Z., Lidholm, Jonas, Papadopoulos, Nikolaos G., Pontoppidan, Bo, Popov, Todor A., Prado, Nayade del, Purohit, Ashok, Reig, Isabel, Seneviratne, Suranjith L., Sinaniotis, Athanasios, Vassilopoulou, Emilia, Versteeg, Serge A., Vieths, Stefan, Zwinderman, Aeilko H., Welsing, Paco M.J., Mills, E.N. Clare, Ballmer-Weber, Barbara K., Knulst, André C., Fernández-Rivas, Montserrat, and Van Ree, Ronald

Published
2021
Full Text
View/download PDF

14. Real-world outcomes following third or subsequent lines of therapy:A Danish population-based study on 189 patients with relapsed/refractory large B-cell lymphomas

Author

AL-Mashhadi, Ahmed Ludvigsen, Jakobsen, Lasse Hjort, Brown, Peter, Gang, Anne Ortved, Thorsteinsson, Anne Luise, Rasoul, Kaziwa, Haissman, Judith Melchior, Tøstesen, Michael Buch, Christoffersen, Mette Niemann, Jelicic, Jelena, Jørgensen, Jennifer Bøgh, Thomsen, Troels, Dessau-Arp, Andriette, Andersen, Andreas P.H., Frederiksen, Mikael, Pedersen, Per Trøllund, Clausen, Michael Roost, Jørgensen, Judit Meszaros, Poulsen, Christian Bjørn, El-Galaly, Tarec Christoffer, Larsen, Thomas Stauffer, AL-Mashhadi, Ahmed Ludvigsen, Jakobsen, Lasse Hjort, Brown, Peter, Gang, Anne Ortved, Thorsteinsson, Anne Luise, Rasoul, Kaziwa, Haissman, Judith Melchior, Tøstesen, Michael Buch, Christoffersen, Mette Niemann, Jelicic, Jelena, Jørgensen, Jennifer Bøgh, Thomsen, Troels, Dessau-Arp, Andriette, Andersen, Andreas P.H., Frederiksen, Mikael, Pedersen, Per Trøllund, Clausen, Michael Roost, Jørgensen, Judit Meszaros, Poulsen, Christian Bjørn, El-Galaly, Tarec Christoffer, and Larsen, Thomas Stauffer

Abstract

Outcome data of patients with relapsed/refractory (R/R) diffuse large B-cell lymphoma (DLBCL) beyond the second line are scarce outside of clinical trials. Novel therapies in the R/R setting have been approved based on single-arm trials, but results need to be contextualized by real-world outcomes. Medical records from 3753 Danish adults diagnosed with DLBCL were reviewed. Patients previously treated with rituximab and anthracycline-based chemotherapy who received the third or later line (3 L+) of treatment after 1 January 2015, were included. Only 189 patients with a median age of 71 years were eligible. The median time since the last line of therapy was 6 months. Patients were treated with either best supportive care (22%), platinum-based salvage therapy (13%), low-intensity chemotherapy (22%), in clinical trial (14%) or various combination treatments (32%). The 2-year OS-/PFS estimates were 25% and 12% for all patients and 49% and 17% for those treated with platinum-based salvage therapy. Age ≥70, CNS involvement, elevated LDH and ECOG ≥2 predicted poor outcomes, and patients with 0–1 of these risk factors had a 2-year OS estimate of 65%. Only a very small fraction of DLBCL patients received third-line treatment and were eligible for inclusion. Outcomes were generally poor, but better in intensively treated, fit young patients with limited disease., Outcome data of patients with relapsed/refractory (R/R) diffuse large B-cell lymphoma (DLBCL) beyond the second line are scarce outside of clinical trials. Novel therapies in the R/R setting have been approved based on single-arm trials, but results need to be contextualized by real-world outcomes. Medical records from 3753 Danish adults diagnosed with DLBCL were reviewed. Patients previously treated with rituximab and anthracycline-based chemotherapy who received the third or later line (3 L+) of treatment after 1 January 2015, were included. Only 189 patients with a median age of 71 years were eligible. The median time since the last line of therapy was 6 months. Patients were treated with either best supportive care (22%), platinum-based salvage therapy (13%), low-intensity chemotherapy (22%), in clinical trial (14%) or various combination treatments (32%). The 2-year OS-/PFS estimates were 25% and 12% for all patients and 49% and 17% for those treated with platinum-based salvage therapy. Age ≥70, CNS involvement, elevated LDH and ECOG ≥2 predicted poor outcomes, and patients with 0–1 of these risk factors had a 2-year OS estimate of 65%. Only a very small fraction of DLBCL patients received third-line treatment and were eligible for inclusion. Outcomes were generally poor, but better in intensively treated, fit young patients with limited disease.

Published
2024

15. Risk of dementia among older patients with lymphoma:A Danish nationwide matched cohort study

Author

Maksten, Eva Futtrup, Jakobsen, Lasse Hjort, Modrau, Boris, Jensvoll, Hilde, Kragholm, Kristian Hay, Jørgensen, Judit Mészáros, Clausen, Michael Roost, Pedersen, Robert Schou, Dessau-Arp, Andriette, Larsen, Thomas Stauffer, Poulsen, Christian Bjørn, Gang, Anne Ortved, Brown, Peter, El-Galaly, Tarec C., Severinsen, Marianne Tang, Maksten, Eva Futtrup, Jakobsen, Lasse Hjort, Modrau, Boris, Jensvoll, Hilde, Kragholm, Kristian Hay, Jørgensen, Judit Mészáros, Clausen, Michael Roost, Pedersen, Robert Schou, Dessau-Arp, Andriette, Larsen, Thomas Stauffer, Poulsen, Christian Bjørn, Gang, Anne Ortved, Brown, Peter, El-Galaly, Tarec C., and Severinsen, Marianne Tang

Abstract

Introduction Treatment of lymphoma can be associated with cognitive challenges, and some patients may fear development of dementia as long-term complication. Studies report a lower risk of dementia after cancer. Some believe this difference to be a protective mechanism of cancer, others believe it to be driven by bias. The risk of developing dementia after lymphoma has not been investigated in a population-based setting. The aim of this study was to identify the risk of being diagnosed with dementia after lymphoma treatment. Materials and Methods This Danish nationwide matched cohort study included patients aged ≥65 years with a first-time diagnosis of a non-central nervous system lymphoma between 2005 and 2018 in complete remission after treatment with chemotherapy. Patients diagnosed with dementia or treated with dementia medication before lymphoma diagnosis were excluded. Each patient was matched 1:5 on sex, year of birth, and a modified Charlson comorbidity index. Patients and matched comparators were followed from the corresponding patient's date of complete remission. The risk of developing dementia was calculated using cause-specific hazard ratios (HR), and the cumulative risk was estimated by Aalen-Johansen with death as the competing risk. Results A total of 3,244 patients and 16,220 matched comparators were included in the study. There was no difference in risk of all-cause dementia among patients with lymphoma compared to matched comparators with cause-specific HR of 0.85 (95% confidence interval [CI]: 0.70;1.04). The risk of both Alzheimer's disease and non-Alzheimer's dementia was equal among patients and comparators: HR 0.89 (95% CI: 0.66;1.21) and 0.82 (95% CI: 0.63;1.07), respectively. Stratified by lymphoma subtype, age, or year of diagnosis, the risk of all-cause dementia remained equal among patients and matched comparators. The cumulative risk of all-cause dementia was significantly lower among patients with lymphoma, Introduction: Treatment of lymphoma can be associated with cognitive challenges, and some patients may fear development of dementia as long-term complication. Studies report a lower risk of dementia after cancer. Some believe this difference to be a protective mechanism of cancer, others believe it to be driven by bias. The risk of developing dementia after lymphoma has not been investigated in a population-based setting. The aim of this study was to identify the risk of being diagnosed with dementia after lymphoma treatment. Materials and Methods: This Danish nationwide matched cohort study included patients aged ≥65 years with a first-time diagnosis of a non-central nervous system lymphoma between 2005 and 2018 in complete remission after treatment with chemotherapy. Patients diagnosed with dementia or treated with dementia medication before lymphoma diagnosis were excluded. Each patient was matched 1:5 on sex, year of birth, and a modified Charlson comorbidity index. Patients and matched comparators were followed from the corresponding patient's date of complete remission. The risk of developing dementia was calculated using cause-specific hazard ratios (HR), and the cumulative risk was estimated by Aalen-Johansen with death as the competing risk. Results: A total of 3,244 patients and 16,220 matched comparators were included in the study. There was no difference in risk of all-cause dementia among patients with lymphoma compared to matched comparators with cause-specific HR of 0.85 (95% confidence interval [CI]: 0.70;1.04). The risk of both Alzheimer's disease and non-Alzheimer's dementia was equal among patients and comparators: HR 0.89 (95% CI: 0.66;1.21) and 0.82 (95% CI: 0.63;1.07), respectively. Stratified by lymphoma subtype, age, or year of diagnosis, the risk of all-cause dementia remained equal among patients and matched comparators. The cumulative risk of all-cause dementia was significantly lower among patients with lymphoma compared to matched com

Published
2024

16. Recommendations for asthma monitoring in children:A PeARL document endorsed by APAPARI, EAACI, INTERASMA, REG, and WAO

Author

Papadopoulos, Nikolaos G., Custovic, Adnan, Deschildre, Antoine, Gern, James E., Nieto Garcia, Antonio, Miligkos, Michael, Phipatanakul, Wanda, Wong, Gary, Xepapadaki, Paraskevi, Agache, Ioana, Arasi, Stefania, Awad El-Sayed, Zeinab, Bacharier, Leonard B., Bonini, Matteo, Braido, Fulvio, Caimmi, Davide, Castro-Rodriguez, Jose A., Chen, Zhimin, Clausen, Michael, Craig, Timothy, Diamant, Zuzana, Ducharme, Francine M., Ebisawa, Motohiro, Eigenmann, Philippe, Feleszko, Wojciech, Fierro, Vincezo, Fiocchi, Alessandro, Garcia-Marcos, Luis, Goh, Anne, Gómez, René Maximiliano, Gotua, Maia, Hamelmann, Eckard, Hedlin, Gunilla, Hossny, Elham M., Ispayeva, Zhanat, Jackson, Daniel J., Jartti, Tuomas, Jeseňák, Miloš, Kalayci, Omer, Kaplan, Alan, Konradsen, Jon R., Kuna, Piotr, Lau, Susanne, Le Souef, Peter, Lemanske, Robert F., Levin, Michael, Makela, Mika J., Mathioudakis, Alexander G., Mazulov, Oleksandr, Morais-Almeida, Mário, Murray, Clare, Nagaraju, Karthik, Novak, Zoltan, Pawankar, Ruby, Pijnenburg, Marielle W., Pite, Helena, Pitrez, Paulo M., Pohunek, Petr, Price, David, Priftanji, Alfred, Ramiconi, Valeria, Rivero Yeverino, Daniela, Roberts, Graham, Sheikh, Aziz, Shen, Kun Ling, Szepfalusi, Zsolt, Tsiligianni, Ioanna, Turkalj, Mirjana, Turner, Steve, Umanets, Tetiana, Valiulis, Arunas, Vijveberg, Susanne, Wang, Jiu Yao, Winders, Tonya, Yon, Dong Keon, Yusuf, Osman M., Zar, Heather J., Papadopoulos, Nikolaos G., Custovic, Adnan, Deschildre, Antoine, Gern, James E., Nieto Garcia, Antonio, Miligkos, Michael, Phipatanakul, Wanda, Wong, Gary, Xepapadaki, Paraskevi, Agache, Ioana, Arasi, Stefania, Awad El-Sayed, Zeinab, Bacharier, Leonard B., Bonini, Matteo, Braido, Fulvio, Caimmi, Davide, Castro-Rodriguez, Jose A., Chen, Zhimin, Clausen, Michael, Craig, Timothy, Diamant, Zuzana, Ducharme, Francine M., Ebisawa, Motohiro, Eigenmann, Philippe, Feleszko, Wojciech, Fierro, Vincezo, Fiocchi, Alessandro, Garcia-Marcos, Luis, Goh, Anne, Gómez, René Maximiliano, Gotua, Maia, Hamelmann, Eckard, Hedlin, Gunilla, Hossny, Elham M., Ispayeva, Zhanat, Jackson, Daniel J., Jartti, Tuomas, Jeseňák, Miloš, Kalayci, Omer, Kaplan, Alan, Konradsen, Jon R., Kuna, Piotr, Lau, Susanne, Le Souef, Peter, Lemanske, Robert F., Levin, Michael, Makela, Mika J., Mathioudakis, Alexander G., Mazulov, Oleksandr, Morais-Almeida, Mário, Murray, Clare, Nagaraju, Karthik, Novak, Zoltan, Pawankar, Ruby, Pijnenburg, Marielle W., Pite, Helena, Pitrez, Paulo M., Pohunek, Petr, Price, David, Priftanji, Alfred, Ramiconi, Valeria, Rivero Yeverino, Daniela, Roberts, Graham, Sheikh, Aziz, Shen, Kun Ling, Szepfalusi, Zsolt, Tsiligianni, Ioanna, Turkalj, Mirjana, Turner, Steve, Umanets, Tetiana, Valiulis, Arunas, Vijveberg, Susanne, Wang, Jiu Yao, Winders, Tonya, Yon, Dong Keon, Yusuf, Osman M., and Zar, Heather J.

Abstract

Monitoring is a major component of asthma management in children. Regular monitoring allows for diagnosis confirmation, treatment optimization, and natural history review. Numerous factors that may affect disease activity and patient well-being need to be monitored: response and adherence to treatment, disease control, disease progression, comorbidities, quality of life, medication side-effects, allergen and irritant exposures, diet and more. However, the prioritization of such factors and the selection of relevant assessment tools is an unmet need. Furthermore, rapidly developing technologies promise new opportunities for closer, or even “real-time,” monitoring between visits. Following an approach that included needs assessment, evidence appraisal, and Delphi consensus, the PeARL Think Tank, in collaboration with major international professional and patient organizations, has developed a set of 24 recommendations on pediatric asthma monitoring, to support healthcare professionals in decision-making and care pathway design. (Figure presented.).

Published
2024

18. The role of trephine bone marrow biopsies in the era of measurable residual disease—Results from the CLL10 trial of the German CLL Study Group (GCLLSG).

Author

Kutsch, Nadine, Robrecht, Sandra, Fink, Anna, Lange, Elisabeth, Weide, Rudolf, Kiehl, Michael G., Sökler, Martin, Schlag, Rudolf, Vehling‐Kaiser, Ursula, Köchling, Georg, Plöger, Christoph, Gregor, Michael, Plesner, Torben, Clausen, Michael R., Oschlies, Ilske, Ritgen, Matthias, Herling, Marco, Fischer, Kirsten, Döhner, Hartmut, and Wendtner, Clemens‐Martin

Published
2024
Full Text
View/download PDF

19. Predictors of Food Sensitization in Children and Adults Across Europe

Author

Lyons, Sarah A., Knulst, André C., Burney, Peter G.J., Fernández-Rivas, Montserrat, Ballmer-Weber, Barbara K., Barreales, Laura, Bieli, Christian, Clausen, Michael, Dubakiene, Ruta, Fernández-Perez, Cristina, Jedrzejczak-Czechowicz, Monika, Kowalski, Marek L., Kummeling, Ischa, Mustakov, Tihomir B., van Os-Medendorp, Harmieke, Papadopoulos, Nikolaos G., Popov, Todor A., Potts, James, Xepapadaki, Paraskevi, Welsing, Paco M.J., Mills, E. N. Clare, van Ree, Ronald, and Le, Thuy-My

Published
2020
Full Text
View/download PDF

20. Prevalence of Food Sensitization and Food Allergy in Children Across Europe

Author

Lyons, Sarah A., Clausen, Michael, Knulst, André C., Ballmer-Weber, Barbara K., Fernandez-Rivas, Montserrat, Barreales, Laura, Bieli, Christian, Dubakiene, Ruta, Fernandez-Perez, Cristina, Jedrzejczak-Czechowicz, Monika, Kowalski, Marek L., Kralimarkova, Tanya, Kummeling, Ischa, Mustakov, Tihomir B., Papadopoulos, Nikolaos G., Popov, Todor A., Xepapadaki, Paraskevi, Welsing, Paco M.J., Potts, James, Mills, E.N. Clare, van Ree, Ronald, Burney, Peter G.J., and Le, Thuy-My

Published
2020
Full Text
View/download PDF

22. Risk Factors for Hen's Egg Allergy in Europe: EuroPrevall Birth Cohort

Author

Grimshaw, Kate E.C., Roberts, Graham, Selby, Anna, Reich, Andreas, Butiene, Indra, Clausen, Michael, Dubakiene, Ruta, Fiandor, Ana, Fiocchi, Alessandro, Grabenhenrich, Linus B., Larco, Jose Ignacio, Kowalski, Marek L., Rudzeviciene, Odilija, Papadopoulos, Nikolaos G., Rosenfeld, Leonard, Sigurdardottir, Sigurveig Th., Sprikkelman, Aline B., Schoemaker, Ana A., Xepapadaki, Paraskevi, Mills, E.N. Clare, Keil, Thomas, and Beyer, Kirsten

Published
2020
Full Text
View/download PDF

23. Deep and Durable Responses with Epcoritamab SC Monotherapy in Patients with Relapsed or Refractory Follicular Lymphoma: Data from the Epcore NHL-1 Follicular Lymphoma Dose-Expansion Cohort

Author

Linton, Kim M, primary, Jurczak, Wojciech, additional, Lugtenburg, Pieternella J., additional, Gyan, Emmanuel, additional, Sureda, Anna, additional, Christensen, Jacob Haaber, additional, Hess, Brian, additional, Tilly, Herve, additional, Cordoba, Raul, additional, Lewis, David John, additional, Okada, Craig, additional, Hutchings, Martin, additional, Clausen, Michael Roost, additional, Vitolo, Umberto, additional, Cochrane, Tara, additional, Leppä, Sirpa, additional, Chamuleau, Martine E.D., additional, Conlon, Rebekah, additional, Favaro, Elena, additional, Favaro, Diana, additional, Altıntaş, Işıl, additional, Liu, Yan, additional, and Thieblemont, Catherine, additional

Published
2024
Full Text
View/download PDF

24. Patients in complete remission after R-CHOP(-like) therapy for diffuse large B-cell lymphoma have limited excess use of health care services in Denmark

Author

Jakobsen, Lasse Hjort, Øvlisen, Andreas Kiesbye, Severinsen, Marianne Tang, Bæch, Joachim, Kragholm, Kristian Hay, Glimelius, Ingrid, Gang, Anne Ortved, Jørgensen, Judit Mészáros, Frederiksen, Henrik, Poulsen, Christian Bjørn, Clausen, Michael Roost, Pedersen, Per Trøllund, Pedersen, Robert Schou, Torp-Pedersen, Christian, Eloranta, Sandra, and El-Galaly, Tarec Christoffer

Published
2022
Full Text
View/download PDF

25. Food Allergy in Adults: Substantial Variation in Prevalence and Causative Foods Across Europe

Author

Lyons, Sarah A., Burney, Peter G.J., Ballmer-Weber, Barbara K., Fernandez-Rivas, Montserrat, Barreales, Laura, Clausen, Michael, Dubakiene, Ruta, Fernandez-Perez, Cristina, Fritsche, Philipp, Jedrzejczak-Czechowicz, Monika, Kowalski, Marek L., Kralimarkova, Tanya, Kummeling, Ischa, Mustakov, Tihomir B., Lebens, Ans F.M., van Os-Medendorp, Harmieke, Papadopoulos, Nikolaos G., Popov, Todor A., Sakellariou, Alexandros, Welsing, Paco M.J., Potts, James, Mills, E.N. Clare, van Ree, Ronald, Knulst, André C., and Le, Thuy-My

Published
2019
Full Text
View/download PDF

26. Revisiting beta‐2 microglobulin as a prognostic marker in diffuse large B‐cell lymphoma.

Author

Jelicic, Jelena, Juul‐Jensen, Karen, Bukumiric, Zoran, Runason Simonsen, Mikkel, Roost Clausen, Michael, Ludvigsen Al‐Mashhadi, Ahmed, Schou Pedersen, Robert, Bjørn Poulsen, Christian, Ortved Gang, Anne, Brown, Peter, El‐Galaly, Tarec Christoffer, and Larsen, Thomas Stauffer

Subjects
PROGNOSIS, DIFFUSE large B-cell lymphomas, DISEASE risk factors, OVERALL survival, PROGNOSTIC models
Abstract

Background: Several clinical prognostic models for diffuse large B‐cell lymphoma (DLBCL) have been proposed, including the most commonly used International Prognostic Index (IPI), the National Comprehensive Cancer Network IPI (NCCN‐IPI), and models incorporating beta‐2 microglobulin (β2M). However, the role of β2M in DLBCL patients is not fully understood. Methods: We identified 6075 patients with newly diagnosed DLBCL treated with immunochemotherapy registered in the Danish Lymphoma Registry. Results: A total of 3232 patients had data available to calculate risk scores from each of the nine considered risk models for DLBCL, including a model developed from our population. Three of four models with β2M and NCCN‐IPI performed better than the International Prognostic Indexes (IPI, age‐adjusted IPI, and revised IPI). Five‐year overall survival for high‐ and low‐risk patients were 43.6% and 86.4% for IPI and 34.9% and 96.2% for NCCN‐IPI. In univariate analysis, higher levels of β2M were associated with inferior survival, higher tumor burden (advanced clinical stage and bulky disease), previous malignancy and increased age, and creatinine levels. Furthermore, we developed a model (β2M‐NCCN‐IPI) by adding β2M to NCCN‐IPI (c‐index 0.708) with improved discriminatory ability compared to NCCN‐IPI (c‐index 0.698, p < 0.05) and 5‐year OS of 33.1%, 56.2%, 82.4%, and 96.4% in the high, high‐intermediate, low‐intermediate and low‐risk group, respectively. Conclusion: International Prognostic Indices, except for NCCN‐IPI, fail to accurately discriminate risk groups in the rituximab era. β2M, a readily available marker, could improve the discriminatory performance of NCCN‐IPI and should be re‐evaluated in the development setting of future models for DLBCL. [ABSTRACT FROM AUTHOR]

Published
2024
Full Text
View/download PDF

27. Recommendations for asthma monitoring in children: A PeARL document endorsed by APAPARI, EAACI, INTERASMA, REG, and WAO.

Author

Papadopoulos, Nikolaos G., Custovic, Adnan, Deschildre, Antoine, Gern, James E., Nieto Garcia, Antonio, Miligkos, Michael, Phipatanakul, Wanda, Wong, Gary, Xepapadaki, Paraskevi, Agache, Ioana, Arasi, Stefania, Awad El‐Sayed, Zeinab, Bacharier, Leonard B., Bonini, Matteo, Braido, Fulvio, Caimmi, Davide, Castro‐Rodriguez, Jose A., Chen, Zhimin, Clausen, Michael, and Craig, Timothy

Subjects
ASTHMA in children, MEDICAL personnel, DELPHI method, PATIENT compliance, WELL-being, CELIAC disease, WHEEZE
Abstract

Monitoring is a major component of asthma management in children. Regular monitoring allows for diagnosis confirmation, treatment optimization, and natural history review. Numerous factors that may affect disease activity and patient well‐being need to be monitored: response and adherence to treatment, disease control, disease progression, comorbidities, quality of life, medication side‐effects, allergen and irritant exposures, diet and more. However, the prioritization of such factors and the selection of relevant assessment tools is an unmet need. Furthermore, rapidly developing technologies promise new opportunities for closer, or even "real‐time," monitoring between visits. Following an approach that included needs assessment, evidence appraisal, and Delphi consensus, the PeARL Think Tank, in collaboration with major international professional and patient organizations, has developed a set of 24 recommendations on pediatric asthma monitoring, to support healthcare professionals in decision‐making and care pathway design. [ABSTRACT FROM AUTHOR]

Published
2024
Full Text
View/download PDF

28. Real‐world outcomes following third or subsequent lines of therapy: A Danish population‐based study on 189 patients with relapsed/refractory large B‐cell lymphomas

Author

AL‐Mashhadi, Ahmed Ludvigsen, primary, Jakobsen, Lasse Hjort, additional, Brown, Peter, additional, Gang, Anne Ortved, additional, Thorsteinsson, Anne‐Luise, additional, Rasoul, Kaziwa, additional, Haissman, Judith Melchior, additional, Tøstesen, Michael Buch, additional, Christoffersen, Mette Niemann, additional, Jelicic, Jelena, additional, Jørgensen, Jennifer Bøgh, additional, Thomsen, Troels, additional, Dessau‐Arp, Andriette, additional, Andersen, Andreas P. H., additional, Frederiksen, Mikael, additional, Pedersen, Per Trøllund, additional, Clausen, Michael Roost, additional, Jørgensen, Judit Meszaros, additional, Poulsen, Christian Bjørn, additional, El‐Galaly, Tarec Christoffer, additional, and Larsen, Thomas Stauffer, additional

Published
2023
Full Text
View/download PDF

32. ABCL-422 Subcutaneous Epcoritamab in Patients With Relapsed or Refractory Large B-Cell Lymphoma (EPCORE NHL-1): Pivotal Results from a Phase 2 Study

Author

Thieblemont, Catherine, Phillips, Tycel, Ghesquieres, Herve, Cheah, Chan Y., Clausen, Michael Roost, Cunningham, David, Do, Young Rok, Feldman, Tatyana, Gasiorowski, Robin, Jurczak, Wojciech, Kim, Tae Min, Lewis, David John, van der Poel, Marjolein, Poon, Michelle Limei, Doerr, Thomas, Kilavuz, Nurgul, Chen, Menghui, Sacchi, Mariana, Elliott, Brian, Hutchings, Martin, and Lugtenburg, Pieternella

Published
2022
Full Text
View/download PDF

33. Treatment strategies and outcomes in diffuse large B-cell lymphoma among 1011 patients aged 75 years or older: A Danish population-based cohort study

Author

Juul, Maja Bech, Jensen, Pernille Hammershoej, Engberg, Henriette, Wehberg, Sonja, Dessau-Arp, Andriette, Haziri, Donika, Kristensen, Helene Bjoerg, Baech, Joachim, Schurmann, Lene, Clausen, Michael Roost, Valentin, Rebecca, Knudsen, Lene Meldgaard, Munksgaard, Lars, El-Galaly, Tarec Christoffer, Frederiksen, Henrik, and Larsen, Thomas Stauffer

Published
2018
Full Text
View/download PDF

34. Treatment strategies, outcomes and prognostic factors in 291 patients with secondary CNS involvement by diffuse large B-cell lymphoma

Author

El-Galaly, Tarec Christoffer, Cheah, Chan Yoon, Bendtsen, Mette Dahl, Nowakowski, Grzegorz S., Kansara, Roopesh, Savage, Kerry J., Connors, Joseph M., Sehn, Laurie H., Goldschmidt, Neta, Shaulov, Adir, Farooq, Umar, Link, Brian K., Ferreri, Andrés J.M., Calimeri, Teresa, Cecchetti, Caterina, Dann, Eldad J., Thompson, Carrie A., Inbar, Tsofia, Maurer, Matthew J., Gade, Inger Lise, Juul, Maja Bech, Hansen, Jakob W., Holmberg, Staffan, Larsen, Thomas S., Cordua, Sabrina, Mikhaeel, N. George, Hutchings, Martin, Seymour, John F., Clausen, Michael Roost, Smith, Daniel, Opat, Stephen, Gilbertson, Michael, Thanarajasingam, Gita, and Villa, Diego

Published
2018
Full Text
View/download PDF

36. POSTER: ABCL-517 Phase III Trial of Subcutaneous Epcoritamab + R-CHOP Versus R-CHOP Alone in Patients With Newly Diagnosed Diffuse Large B-Cell Lymphoma (DLBCL): EPCORE DLBCL-2

Author

Sehn, Laurie, primary, Chamuleau, Martine, additional, Lenz, Georg, additional, Clausen, Michael, additional, Haioun, Corinne, additional, Izutsu, Koji, additional, Davies, Andrew, additional, Zhu, Jun, additional, Oki, Toshiko, additional, Szafer-Glusman, Edith, additional, Conlon, Rebekah, additional, Chiou, Hueiyu, additional, Ipe, David, additional, Elliott, Brian, additional, Wu, Jun, additional, and Salles, Gilles, additional

Published
2023
Full Text
View/download PDF

37. ABCL-517 Phase III Trial of Subcutaneous Epcoritamab + R-CHOP Versus R-CHOP Alone in Patients With Newly Diagnosed Diffuse Large B-Cell Lymphoma (DLBCL): EPCORE DLBCL-2

Author

Sehn, Laurie, primary, Chamuleau, Martine, additional, Lenz, Georg, additional, Clausen, Michael, additional, Haioun, Corinne, additional, Izutsu, Koji, additional, Davies, Andrew, additional, Zhu, Jun, additional, Oki, Toshiko, additional, Szafer-Glusman, Edith, additional, Conlon, Rebekah, additional, Chiou, Hueiyu, additional, Ipe, David, additional, Elliott, Brian, additional, Wu, Jun, additional, and Salles, Gilles, additional

Published
2023
Full Text
View/download PDF

38. Oral Abstract: ABCL-500 Longer Follow-Up Reaffirms Subcutaneous Epcoritamab Induces Deep and Durable Complete Remissions in Patients With Relapsed/Refractory Large B-Cell Lymphoma: Updated Results From the Pivotal EPCORE NHL-1 Trial

Author

Karimi, Yasmin, primary, Ghesquieres, Herve, additional, Jurczak, Wojciech, additional, Cheah, Chan Y., additional, Clausen, Michael Roost, additional, Lugtenburg, Pieternella, additional, Cunningham, David, additional, Do, Young Rok, additional, Lewis, David John, additional, Gasiorowski, Robin, additional, Kim, Tae Min, additional, van der Poel, Marjolein, additional, Poon, Michelle Limei, additional, Feldman, Tatyana, additional, Linton, Kim M., additional, Sureda, Anna, additional, Hutchings, Martin, additional, Stirner, Mariana Cota, additional, Liu, Yan, additional, Kilavuz, Nurgul, additional, Sacchi, Mariana, additional, and Thieblemont, Catherine, additional

Published
2023
Full Text
View/download PDF

39. ABCL-429 Epcoritamab + R-CHOP in Patients With Previously Untreated (1L) High-Risk Diffuse Large B-Cell Lymphoma, Including Double-Hit/Triple-Hit Lymphoma: Updated EPCORE NHL-2 Data

Author

Falchi, Lorenzo, primary, Clausen, Michael Roost, additional, Offner, Fritz, additional, de Vos, Sven, additional, Brody, Joshua, additional, Linton, Kim M., additional, Snauwaert, Sylvia, additional, Cordoba, Raul, additional, Wu, Jun, additional, Bykhovski, Irina, additional, Rana, Ali, additional, and Belada, David, additional

Published
2023
Full Text
View/download PDF

40. ABCL-500 Longer Follow-Up Reaffirms Subcutaneous Epcoritamab Induces Deep and Durable Complete Remissions in Patients With Relapsed/Refractory Large B-Cell Lymphoma: Updated Results From the Pivotal EPCORE NHL-1 Trial

Author

Karimi, Yasmin, primary, Ghesquieres, Herve, additional, Jurczak, Wojciech, additional, Cheah, Chan Y., additional, Clausen, Michael Roost, additional, Lugtenburg, Pieternella, additional, Cunningham, David, additional, Do, Young Rok, additional, Lewis, David John, additional, Gasiorowski, Robin, additional, Kim, Tae Min, additional, van der Poel, Marjolein, additional, Poon, Michelle Limei, additional, Feldman, Tatyana, additional, Linton, Kim M., additional, Sureda, Anna, additional, Hutchings, Martin, additional, Stirner, Mariana Cota, additional, Liu, Yan, additional, Kilavuz, Nurgul, additional, Sacchi, Mariana, additional, and Thieblemont, Catherine, additional

Published
2023
Full Text
View/download PDF

41. POSTER: ABCL-500 Longer Follow-Up Reaffirms Subcutaneous Epcoritamab Induces Deep and Durable Complete Remissions in Patients With Relapsed/Refractory Large B-Cell Lymphoma: Updated Results From the Pivotal EPCORE NHL-1 Trial

Author

Karimi, Yasmin, primary, Ghesquieres, Herve, additional, Jurczak, Wojciech, additional, Cheah, Chan Y., additional, Clausen, Michael Roost, additional, Lugtenburg, Pieternella, additional, Cunningham, David, additional, Do, Young Rok, additional, Lewis, David John, additional, Gasiorowski, Robin, additional, Kim, Tae Min, additional, van der Poel, Marjolein, additional, Poon, Michelle Limei, additional, Feldman, Tatyana, additional, Linton, Kim M., additional, Sureda, Anna, additional, Hutchings, Martin, additional, Stirner, Mariana Cota, additional, Liu, Yan, additional, Kilavuz, Nurgul, additional, Sacchi, Mariana, additional, and Thieblemont, Catherine, additional

Published
2023
Full Text
View/download PDF

42. POSTER: ABCL-429 Epcoritamab + R-CHOP in Patients With Previously Untreated (1L) High-Risk Diffuse Large B-Cell Lymphoma, Including Double-Hit/Triple-Hit Lymphoma: Updated EPCORE NHL-2 Data

Author

Falchi, Lorenzo, primary, Clausen, Michael Roost, additional, Offner, Fritz, additional, de Vos, Sven, additional, Brody, Joshua, additional, Linton, Kim M., additional, Snauwaert, Sylvia, additional, Cordoba, Raul, additional, Wu, Jun, additional, Bykhovski, Irina, additional, Rana, Ali, additional, and Belada, David, additional

Published
2023
Full Text
View/download PDF

43. P1118: LONGER FOLLOW-UP FROM THE PIVOTAL EPCORE NHL-1 TRIAL REAFFIRMS SUBCUTANEOUS EPCORITAMAB INDUCES DEEP, DURABLE COMPLETE REMISSIONS IN PATIENTS WITH RELAPSED/REFRACTORY LARGE B-CELL LYMPHOMA

Author

Jurczak, Wojciech, primary, Ghesquieres, Herve, additional, Karimi, Yasmin, additional, Cheah, Chan, additional, Roost Clausen, Michael, additional, Cunningham, David, additional, Rok Do, Young, additional, Lewis, David, additional, Gasiorowski, Robin, additional, Min Kim, Tae, additional, Poel, Marjolein Van Der, additional, Limei Poon, Michelle, additional, Feldman, Tatyana, additional, Linton, Kim, additional, Sureda, Anna, additional, Hutchings, Martin, additional, Kanoun, Salim, additional, Vercellino, Laetitia, additional, Cota Stirner, Mariana, additional, Mcgoldrick, Stephanie, additional, Liu, Yan, additional, Sacchi, Mariana, additional, Lugtenburg, Pieternella, additional, and Thieblemont, Catherine, additional

Published
2023
Full Text
View/download PDF

44. P1676: RISK OF DEMENTIA IN OLDER PATIENTS TREATED WITH CHEMOTHERAPY FOR LYMPHOMA: A DANISH NATIONWIDE COHORT STUDY

Author

Maksten, Eva, primary, Jakobsen, Lasse, additional, Modrau, Boris, additional, Jensvoll, Hilde, additional, Kragholm, Kristian Hay, additional, Jørgensen, Judit, additional, Clausen, Michael Roost, additional, Pedersen, Robert Schou, additional, Dessau-Arp, Andriette, additional, Larsen, Thomas Stauffer, additional, Poulsen, Christian Bjorn, additional, Gang, Anne Ortved, additional, Brown, Peter, additional, El-Galaly, Tarec, additional, and Severinsen, Marianne, additional

Published
2023
Full Text
View/download PDF

45. P1116: HIGH COMPLETE METABOLIC RESPONSE RATES WITH EPCORITAMAB + R-CHOP IN PREVIOUSLY UNTREATED (1L) PATIENTS WITH HIGH-RISK DIFFUSE LARGE B-CELL LYMPHOMA, INCLUDING DOUBLE/TRIPLE-HIT: EPCORE NHL-2 UPDATE

Author

Roost Clausen, Michael, primary, Belada, David, additional, Offner, Fritz, additional, de Vos, Sven, additional, Brody, Joshua, additional, Linton, Kim, additional, Snauwaert, Sylvia, additional, Cordoba, Raul, additional, Wu, Jun, additional, Bykhovski, Irina, additional, Wang, Liwei, additional, Rana, Ali, additional, and Falchi, Lorenzo, additional

Published
2023
Full Text
View/download PDF

46. The number of extranodal sites assessed by PET/CT scan is a powerful predictor of CNS relapse for patients with diffuse large B-cell lymphoma: An international multicenter study of 1532 patients treated with chemoimmunotherapy

Author

El-Galaly, Tarec Christoffer, Villa, Diego, Michaelsen, Thomas Yssing, Hutchings, Martin, Mikhaeel, Nabegh George, Savage, Kerry J., Sehn, Laurie H., Barrington, Sally, Hansen, Jakob W., Smith, Daniel, Rady, Kirsty, Mylam, Karen J., Larsen, Thomas S., Holmberg, Staffan, Juul, Maja B., Cordua, Sabrina, Clausen, Michael R., Jensen, Kristina B., Johnsen, Hans E., Seymour, John F., Connors, Joseph M., de Nully Brown, Peter, Bøgsted, Martin, and Cheah, Chan Y.

Published
2017
Full Text
View/download PDF

47. Real‐world outcomes following third or subsequent lines of therapy: A Danish population‐based study on 189 patients with relapsed/refractory large B‐cell lymphomas.

Author

AL‐Mashhadi, Ahmed Ludvigsen, Jakobsen, Lasse Hjort, Brown, Peter, Gang, Anne Ortved, Thorsteinsson, Anne‐Luise, Rasoul, Kaziwa, Haissman, Judith Melchior, Tøstesen, Michael Buch, Christoffersen, Mette Niemann, Jelicic, Jelena, Jørgensen, Jennifer Bøgh, Thomsen, Troels, Dessau‐Arp, Andriette, Andersen, Andreas P. H., Frederiksen, Mikael, Pedersen, Per Trøllund, Clausen, Michael Roost, Jørgensen, Judit Meszaros, Poulsen, Christian Bjørn, and El‐Galaly, Tarec Christoffer

Subjects
RITUXIMAB, DIFFUSE large B-cell lymphomas, LYMPHOMAS, DISEASE risk factors, SALVAGE therapy, DANES
Abstract

Summary: Outcome data of patients with relapsed/refractory (R/R) diffuse large B‐cell lymphoma (DLBCL) beyond the second line are scarce outside of clinical trials. Novel therapies in the R/R setting have been approved based on single‐arm trials, but results need to be contextualized by real‐world outcomes. Medical records from 3753 Danish adults diagnosed with DLBCL were reviewed. Patients previously treated with rituximab and anthracycline‐based chemotherapy who received the third or later line (3 L+) of treatment after 1 January 2015, were included. Only 189 patients with a median age of 71 years were eligible. The median time since the last line of therapy was 6 months. Patients were treated with either best supportive care (22%), platinum‐based salvage therapy (13%), low‐intensity chemotherapy (22%), in clinical trial (14%) or various combination treatments (32%). The 2‐year OS‐/PFS estimates were 25% and 12% for all patients and 49% and 17% for those treated with platinum‐based salvage therapy. Age ≥70, CNS involvement, elevated LDH and ECOG ≥2 predicted poor outcomes, and patients with 0–1 of these risk factors had a 2‐year OS estimate of 65%. Only a very small fraction of DLBCL patients received third‐line treatment and were eligible for inclusion. Outcomes were generally poor, but better in intensively treated, fit young patients with limited disease. [ABSTRACT FROM AUTHOR]

Published
2024
Full Text
View/download PDF

48. Phase 3 trial of subcutaneous epcoritamab + R-CHOP versus R-CHOP in patients (pts) with newly diagnosed diffuse large B-cell lymphoma (DLBCL): EPCORE DLBCL-2.

Author

Sehn, Laurie Helen, primary, Chamuleau, Martine, additional, Lenz, Georg, additional, Clausen, Michael, additional, Haioun, Corinne, additional, Izutsu, Koji, additional, Davies, Andrew John John, additional, Zhu, Jun, additional, Oki, Toshiko, additional, Szafer-Glusman, Edith, additional, Conlon, Rebekah, additional, Chiou, Hueiyu, additional, Ipe, David, additional, Elliott, Brian, additional, Wu, Jun, additional, and Salles, Gilles A., additional

Published
2023
Full Text
View/download PDF

49. Deep learning-based algorithm accurately classifies sleep stages in preadolescent children with sleep-disordered breathing symptoms and age-matched controls

Author

Somaskandhan, Pranavan, primary, Leppänen, Timo, additional, Terrill, Philip I., additional, Sigurdardottir, Sigridur, additional, Arnardottir, Erna Sif, additional, Ólafsdóttir, Kristín A., additional, Serwatko, Marta, additional, Sigurðardóttir, Sigurveig Þ., additional, Clausen, Michael, additional, Töyräs, Juha, additional, and Korkalainen, Henri, additional

Published
2023
Full Text
View/download PDF

50. Work Disability and Return to Work After Lymphoma: A Danish Nationwide Cohort Study

Author

Maksten,Eva Futtrup, Jakobsen,Lasse Hjort, Kragholm,Kristian Hay, Baech,Joachim, Andersen,Mikkel Porsborg, Madsen,Jakob, Jørgensen,Judit Mészáros, Clausen,Michael Roost, Pedersen,Robert Schou, Dessau-Arp,Andriette, Larsen,Thomas Stauffer, Poulsen,Christian Bjørn, Gang,Anne Ortved, Brown,Peter, Fonager,Kirsten, El-Galaly,Tarec C, Severinsen,Marianne Tang, Maksten,Eva Futtrup, Jakobsen,Lasse Hjort, Kragholm,Kristian Hay, Baech,Joachim, Andersen,Mikkel Porsborg, Madsen,Jakob, Jørgensen,Judit Mészáros, Clausen,Michael Roost, Pedersen,Robert Schou, Dessau-Arp,Andriette, Larsen,Thomas Stauffer, Poulsen,Christian Bjørn, Gang,Anne Ortved, Brown,Peter, Fonager,Kirsten, El-Galaly,Tarec C, and Severinsen,Marianne Tang

Abstract

Eva Futtrup Maksten,1,2 Lasse Hjort Jakobsen,1,3 Kristian Hay Kragholm,4 Joachim Baech,1,2 Mikkel Porsborg Andersen,5 Jakob Madsen,1,2 Judit Mészáros Jørgensen,6 Michael Roost Clausen,7 Robert Schou Pedersen,8 Andriette Dessau-Arp,9 Thomas Stauffer Larsen,10 Christian Bjørn Poulsen,11 Anne Ortved Gang,12 Peter Brown,12 Kirsten Fonager,2,13 Tarec C El-Galaly,1,2 Marianne Tang Severinsen1,2 1Department of Haematology, Clinical Cancer Research Unit, Aalborg University Hospital, Aalborg, Denmark; 2Department of Clinical Medicine, Aalborg University, Aalborg, Denmark; 3Department Mathematical Sciences, Aalborg University, Aalborg, Denmark; 4Department of Cardiology & Unit of Epidemiology and Biostatistics, Aalborg University Hospital, Aalborg, Denmark; 5Department of Cardiology, Nordsjaellands Hospital, Hillerød, Denmark; 6Department of Haematology, Aarhus University Hospital, Aarhus, Denmark; 7Department of Haematology, Vejle Hospital, Vejle, Denmark; 8Department of Medicine, Section of Haematology, Regionshospital Goedstrup, Goedstrup, Denmark; 9Department of Haematology, Hospital South West Jutland, Esbjerg, Denmark; 10Department of Haematology, Odense University Hospital, Odense, Denmark; 11Department of Haematology, Zealand University Hospital, Roskilde, Denmark; 12Department of Haematology, Rigshospitalet, Copenhagen University Hospital, Copenhagen and Department of Clinical Medicine, University of Copenhagen, Copenhagen, Denmark; 13Department of Social Medicine, Aalborg University Hospital, Aalborg, DenmarkCorrespondence: Eva Futtrup Maksten, Department of Haematology, Clinical Cancer Research Unit, Aalborg University Hospital, Sdr. Skovvej 15, Aalborg, 9000, Denmark, Tel +45 97663872, Fax + 45 97666323, Email efm@rn.dkPurpose: Many patients diagnosed with lymphoma are of working age. Cancer patients are known to have a higher risk of sick leave and disability pension, but this has only been delineated for certain subtypes of lymphoma. Therefore, this stu

Published
2023

Catalog

Books, media, physical & digital resources
See catalog results